Jasmine Lichfield

Clinical Lead Astellas Pharma

Seminars

Monday 23rd February 2026
Delving Into Padcev-Keytruda Clinical Performance in Urothelial Cancer to Understand the Potential of ADC Combinations to Reshape Standard of Care Therapies
9:30 am
  • Overviewing enfortumab vedotin (EV) and combining with pembrolizumab
  • Reflecting on previous clinical data of EV in combination with pembrolizumab in locally advanced or metastatic urothelial cancer
  • Exploring recent clinical combination data of EV-pembrolizumab combinations with pembrolizumab in muscle-invasive bladder cancer
Jasmine Lichfield Speaker Photo - 16th World ADC London Summit